X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs DISHMAN PHARMA - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA DISHMAN PHARMA TORRENT PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 43.6 25.1 173.7% View Chart
P/BV x 6.2 3.3 184.0% View Chart
Dividend Yield % 0.8 0.7 125.3%  

Financials

 TORRENT PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
DISHMAN PHARMA
Mar-16
TORRENT PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,550374 414.0%   
Low Rs1,144129 887.1%   
Sales per share (Unadj.) Rs354.7197.8 179.3%  
Earnings per share (Unadj.) Rs40.121.2 189.0%  
Cash flow per share (Unadj.) Rs64.234.7 185.0%  
Dividends per share (Unadj.) Rs14.002.00 700.0%  
Dividend yield (eoy) %1.00.8 130.8%  
Book value per share (Unadj.) Rs273.1179.9 151.8%  
Shares outstanding (eoy) m169.2280.69 209.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.81.3 298.4%   
Avg P/E ratio x33.611.9 283.2%  
P/CF ratio (eoy) x21.07.2 289.3%  
Price / Book Value ratio x4.91.4 352.5%  
Dividend payout %34.99.4 370.4%   
Avg Mkt Cap Rs m227,89720,306 1,122.3%   
No. of employees `00014.70.8 1,773.2%   
Total wages/salary Rs m11,3535,355 212.0%   
Avg. sales/employee Rs Th4,083.019,252.7 21.2%   
Avg. wages/employee Rs Th772.36,459.5 12.0%   
Avg. net profit/employee Rs Th461.32,064.1 22.4%   
INCOME DATA
Net Sales Rs m60,02115,961 376.1%  
Other income Rs m2,988265 1,126.0%   
Total revenues Rs m63,00916,226 388.3%   
Gross profit Rs m13,4934,103 328.8%  
Depreciation Rs m4,0861,091 374.7%   
Interest Rs m3,085944 326.6%   
Profit before tax Rs m9,3102,334 399.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,529624 405.5%   
Profit after tax Rs m6,7811,711 396.3%  
Gross profit margin %22.525.7 87.4%  
Effective tax rate %27.226.7 101.6%   
Net profit margin %11.310.7 105.4%  
BALANCE SHEET DATA
Current assets Rs m52,62311,018 477.6%   
Current liabilities Rs m52,0229,517 546.6%   
Net working cap to sales %1.09.4 10.7%  
Current ratio x1.01.2 87.4%  
Inventory Days Days120110 108.2%  
Debtors Days Days7635 218.8%  
Net fixed assets Rs m85,01616,304 521.4%   
Share capital Rs m846161 524.3%   
"Free" reserves Rs m45,37612,907 351.6%   
Net worth Rs m46,22214,516 318.4%   
Long term debt Rs m41,1154,189 981.4%   
Total assets Rs m142,43229,805 477.9%  
Interest coverage x4.03.5 115.8%   
Debt to equity ratio x0.90.3 308.2%  
Sales to assets ratio x0.40.5 78.7%   
Return on assets %6.98.9 77.7%  
Return on equity %14.711.8 124.5%  
Return on capital %14.217.5 81.0%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m14,5804,952 294.5%   
Fx outflow Rs m3,600697 516.6%   
Net fx Rs m10,9804,255 258.1%   
CASH FLOW
From Operations Rs m8,9422,786 320.9%  
From Investments Rs m-47,070-1,529 3,078.7%  
From Financial Activity Rs m34,174-941 -3,631.3%  
Net Cashflow Rs m-3,655316 -1,155.2%  

Share Holding

Indian Promoters % 71.5 61.4 116.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 3.7 189.7%  
FIIs % 12.6 12.7 99.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 22.1 39.8%  
Shareholders   26,511 46,261 57.3%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  AUROBINDO PHARMA  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Slumps Over 530 Points(Closing)

Share markets in India continued their sell-off seen during the last week and ended the day deep in the red. All sectoral indices traded on a negative note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7% (Quarterly Result Update)

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Sep 24, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS